

**EXIT OFFER PUBLIC ANNOUNCEMENT
FOR THE ATTENTION OF THE EQUITY SHAREHOLDERS OF
FRESENIUS KABI ONCOLOGY LIMITED**

Registered office: B-310, Som Datt Chambers - I, Bhikaji Cama Place, New Delhi-110066. **Tel:** +91 124 4885000;
Fax: +91 124 4885003; **Email:** contactus.india@fresenius-kabi.com; **Website:** www.fresenius-kabi-oncology.com
Fresenius Kabi Oncology Limited was originally incorporated under the name of 'Dabur Pharma Limited' on March 18, 2003. Vide a fresh certificate of incorporation issued on January 9, 2009, its name was changed to 'Fresenius Kabi Oncology Limited'.

This public announcement ("**Exit Offer PA**") is being issued by Fresenius Kabi (Singapore) Pte Limited ("**Acquirer**") to provide the public shareholders of Fresenius Kabi Oncology Limited ("**Company**") an exit opportunity in accordance with Regulation 21 of the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 ("**Delisting Regulations**"). This Exit Offer PA is in continuation of and should be read in conjunction with the public announcement dated September 16, 2013 ("**Public Announcement**") and letter of offer dated September 14, 2013 ("**Letter of Offer**"), as amended by the first corrigendum to the Public Announcement and the Letter of Offer published on October 13, 2013, the second corrigendum to the Public Announcement and the Letter of Offer published on October 19, 2013, the supplement to the second corrigendum (to the Public Announcement and the Letter of Offer) published on October 22, 2013 and the public announcement on success of the delisting offer dated October 30, 2013 ("**Post Offer PA**").

Capitalised terms used but not defined in this Exit Offer PA shall have the same meaning assigned to them as in the Public Announcement and the Letter of Offer.

1. INTIMATION OF DATE OF DELISTING

Pursuant to the Delisting Offer made by the Acquirer to the public shareholders of the Company and the Post Offer PA, the Company had applied for the delisting of its Shares from the BSE and NSE on November 1, 2013.

BSE vide its notice no. 20131220-27 dated December 20, 2013 has communicated that trading in the Shares of the Company will be discontinued with effect from January 3, 2014 (i.e. w.e.f. closing hours of trading on January 2, 2014) and the Shares of the Company will be delisted from BSE with effect from January 10, 2014. NSE, vide its circular reference no. 1073/2013 has communicated that trading in the Shares of the Company will be discontinued with effect from January 3, 2014 (i.e. w.e.f. closing hours of trading on January 2, 2014) and the Shares of the Company will be delisted from NSE with effect from January 10, 2014.

It may be noted that the Securities and Exchange Board of India ("**SEBI**") has informed the BSE and NSE vide its letter dated December 20, 2013 that SEBI has filed an appeal in this matter before the Hon'ble Supreme Court of India and the outcome of the same is awaited.

The delisting of the Shares means that they will no longer be traded on the BSE and NSE and a liquid market for trading of the Shares will cease to exist.

2. OUTSTANDING SHARES AFTER DELISTING

In accordance with Regulation 21 (1) of the Delisting Regulations, and as announced earlier in the Post Offer PA, the remaining public shareholders of the Company who did not or were not able to participate in the reverse book building ("**RBB**") process or who unsuccessfully tendered Shares in the RBB process ("**Residual Shareholders**") will be able to offer their Shares to the Acquirer at the price of Rs. 135 per Share ("**Exit Price**") for a minimum period of one year starting from the date of delisting of the Shares from BSE and NSE ("**Date of Delisting**") i.e. from January 10, 2014 to January 9, 2015 ("**Exit Period**"), on the terms and subject to the conditions set out below and in the Exit Offer Letter (as defined below).

An offer letter ("**Exit Offer Letter**") in this regard shall be despatched to the Residual Shareholders whose names appear on the register of members of the Company as on the Date of Delisting, giving details about the exit opportunity available to Residual Shareholders and the procedure to be followed for tendering of their Shares to the Acquirer during the Exit Period. In the event of any Residual Shareholder not receiving, or misplacing their Exit Offer Letter, they may obtain a copy by writing to the Registrar to the Exit Offer, clearly marking the envelope "**FRESENIUS KABI ONCOLOGY LIMITED - EXIT OFFER**". The Exit Offer Letter and the accompanying application form can also be downloaded from the website of the Registrar to the Exit Offer, www.linkintime.com or from the website of the Company at www.fresenius-kabi-oncology.com or by sending an email request to fkol.delisting@linkintime.co.in.

3. PAYMENT OF CONSIDERATION TO RESIDUAL SHAREHOLDERS

Subject fulfilment of the terms and conditions specified in the Exit Offer Letter, the Acquirer shall make payments on a monthly basis, within 10 working days of the immediately subsequent calendar month from the date of receipt by the Registrar to the Exit Offer, of the duly filled valid application forms along with necessary documentation for tendering the Shares, as identified in the Exit Offer Letter. Payments will be made only to those Residual Shareholders who have validly tendered their Shares, by following the instructions laid down in the Exit Offer Letter and the application form enclosed therewith. The Acquirer reserves the right to make the payment earlier.

4. The Acquirer will inform the Residual Shareholders by way of a public announcement of any changes to the information set out in this Exit Offer PA or the Exit Offer Letter.

All queries may be directed to the Registrar to the Exit Offer or the Manager to the Exit Offer.

MANAGER TO THE EXIT OFFER	REGISTRAR TO THE EXIT OFFER
<p>BofA Merrill Lynch</p> <p>DSP Merrill Lynch Limited Registered Office: 8th Floor, Mafatlal Centre, Nariman Point, Mumbai- 400 021 New Delhi Address: 2nd Floor, DLF Centre, Sansad Marg, New Delhi - 110 001 Tel: +91 22 6632 8000; Fax: +91 22 2204 8518 Email: dg.fkol_delisting@baml.com Contact Person: Kamna Sahni</p>	<p>LINK INTIME INDIA PVT LTD</p> <p>Link Intime India Private Limited Address: C-13, Pannalal Silk Mills Compound, LBS Marg, Bhandup West, Mumbai- 400078 Tel: +91 22 2596 7878 Fax: +91 22 2596 0329 Email: fkol.delisting@linkintime.co.in Contact Person: Pravin Kasare</p>

For Fresenius Kabi (Singapore) Pte Ltd
(On behalf of the Board)

Sd/-
Name: Gerrit Steen
Designation: Director
Date: December 27, 2013

Sd/-
Name: Mats Christer Henriksson
Designation: Director
Date: December 27, 2013